-----BEGIN PRIVACY-ENHANCED MESSAGE-----
Proc-Type: 2001,MIC-CLEAR
Originator-Name: webmaster@www.sec.gov
Originator-Key-Asymmetric:
MFgwCgYEVQgBAQICAf8DSgAwRwJAW2sNKK9AVtBzYZmr6aGjlWyK3XmZv3dTINen
TWSM7vrzLADbmYQaionwg5sDW3P6oaM5D3tdezXMm7z1T+B+twIDAQAB
MIC-Info: RSA-MD5,RSA,
MruHJdaR5bn19HiX4562tjzLNlferVW3Q8Ho1rCAhPP8E3ohzegiAqIKU/br7t7i
O2uvoms5tZDJXwpOU7BuwA==
<SEC-DOCUMENT>0001041885-10-000027.txt : 20100113
<SEC-HEADER>0001041885-10-000027.hdr.sgml : 20100113
<ACCEPTANCE-DATETIME>20100113104555
ACCESSION NUMBER: 0001041885-10-000027
CONFORMED SUBMISSION TYPE: SC 13G/A
PUBLIC DOCUMENT COUNT: 1
FILED AS OF DATE: 20100113
DATE AS OF CHANGE: 20100113
SUBJECT COMPANY:
COMPANY DATA:
COMPANY CONFORMED NAME: ALSERES PHARMACEUTICALS INC /DE
CENTRAL INDEX KEY: 0000094784
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
IRS NUMBER: 870277826
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
FILING VALUES:
FORM TYPE: SC 13G/A
SEC ACT: 1934 Act
SEC FILE NUMBER: 005-07548
FILM NUMBER: 10524183
BUSINESS ADDRESS:
STREET 1: 239 SOUTH STREET
CITY: HOPKINTON
STATE: MA
ZIP: 01748
BUSINESS PHONE: 508-497-2360
MAIL ADDRESS:
STREET 1: 239 SOUTH STREET
CITY: HOPKINTON
STATE: MA
ZIP: 01748
FORMER COMPANY:
FORMER CONFORMED NAME: BOSTON LIFE SCIENCES INC /DE
DATE OF NAME CHANGE: 19950706
FORMER COMPANY:
FORMER CONFORMED NAME: GREENWICH PHARMACEUTICALS INC
DATE OF NAME CHANGE: 19920703
FORMER COMPANY:
FORMER CONFORMED NAME: STRATEGIC MEDICAL RESEARCH CORP /DE
DATE OF NAME CHANGE: 19790521
FILED BY:
COMPANY DATA:
COMPANY CONFORMED NAME: INGALLS & SNYDER LLC
CENTRAL INDEX KEY: 0001041885
IRS NUMBER: 135156620
STATE OF INCORPORATION: NY
FISCAL YEAR END: 0930
FILING VALUES:
FORM TYPE: SC 13G/A
BUSINESS ADDRESS:
STREET 1: 61 BROADWAY
STREET 2: C/O INGALLS & SNYDER
CITY: NEW YORK
STATE: NY
ZIP: 100006
BUSINESS PHONE: 2122697812
MAIL ADDRESS:
STREET 1: 61 BROADWAY
CITY: NEW YORK
STATE: NY
ZIP: 100006
</SEC-HEADER>
<DOCUMENT>
<TYPE>SC 13G/A
<SEQUENCE>1
<FILENAME>alspha13gaisdec09.txt
<TEXT>
UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
_____________________________
OMB APPROVAL
OMB NUMBER: 3235-0145
Expires: December 31, 2005
Estimated average burden
hours per response....11
_____________________________
SCHEDULE 13G/A
Under the Securities Exchange Act of 1934
(Amendment No.__5___ )*
ALSERES PHARMACEUTICALS, INC.
-----------------------------------------------------
(Name of Issuer)
COMMON STOCK
-----------------------------------------------------
(Title of Class of Securities)
021152103
-----------------------------------------------------
(CUSIP Number)
12/31/09
-----------------------------------------------------
(Date of Event Which Requires Filing of this Statement)
Check the appropriate box to designate the rule pursuant to which this Schedule
is filed:
[x] Rule 13d-1(b)
[] Rule 13d-1(c)
[] Rule 13d-1(d)
- ----------
*The remainder of this cover page shall be filled out for a reporting person's
initial filing on this form with respect to the subject class of securities, and
for any subsequent amendment containing information which would alter the
disclosures provided in a prior cover page.
The information required in the remainder of this cover page shall not be deemed
to be "filed" for the purpose of Section 18 of the Securities Exchange Act of
1934 ("Act") or otherwise subject to the liabilities of that section of the Act
but shall be subject to all other provisions of the Act (however, see the
Notes).
<PAGE>
CUSIP No. 021152103
- --------------------------------------------------------------------------------
1. NAME OF REPORTING PERSON(S)
S.S. OR I.R.S. IDENTIFICATION NO. OF ABOVE PERSON(S)
INGALLS & SNYDER LLC
13-5156620
- --------------------------------------------------------------------------------
2. CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP*
(a) [ ]
(b) [ ]
- --------------------------------------------------------------------------------
3. SEC USE ONLY
- --------------------------------------------------------------------------------
4. CITIZENSHIP OR PLACE OF ORGANIZATION
NEW YORK STATE
- --------------------------------------------------------------------------------
NUMBER OF 5. SOLE VOTING POWER
SHARES 0
BENEFICIALLY --------------------------------------------------------------
OWNED BY 6. SHARED VOTING POWER
EACH 0
REPORTING --------------------------------------------------------------
PERSON 7. SOLE DISPOSITIVE POWER
WITH 0
- --------------------------------------------------------------
8. SHARED DISPOSITIVE POWER
2,825,205
- --------------------------------------------------------------------------------
9. AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
2,825,205
- --------------------------------------------------------------------------------
10. CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES*
- --------------------------------------------------------------------------------
11. PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)
9.9%
- --------------------------------------------------------------------------------
12. TYPE OF REPORTING PERSON*
BD, IA
- --------------------------------------------------------------------------------
Item 1. (a) Name of Issuer:
ALSERES PHARMACEUTICALS, INC.
--------------------------------------------------------------
(b) Address of Issuer's Principal Executive Offices:
239 SOUTH STREET
HOPKINTON, MA 01748
--------------------------------------------------------------
Item 2. (a) Name of Person Filing:
INGALLS & SNYDER LLC
--------------------------------------------------------------
(b) Address of Principal Business Office, or if None, Residence:
61 BROADWAY, NEW YORK, NY 10006
--------------------------------------------------------------
(c) Citizenship:
NEW YORK STATE
--------------------------------------------------------------
(d) Title of Class of Securities:
COMMON STOCK
--------------------------------------------------------------
(e) CUSIP Number:
021152103
--------------------------------------------------------------
Item 3. If this statement is filed pursuant to Rules 240.13d-(1), or
13d-2(b) or (c), check whether the person filing is a:
(a) [X] Broker or Dealer registered under Section 15 of the
Act, (15 U.S.C 78o)
(b) [ ] Bank as defined in Section 3(a)(6) of the
Act, (15 U.S.C 78c)
(c) [ ] Insurance Company as defined in Section 3(a)(19) of
the Act, (15 U.S.C 78c)
(d) [ ] Investment Company registered under Section 8 of the
Investment Company Act of 1940 (15 U.S.C 80a-8)
(e) [X] Investment Adviser in accordance with Section
240.13d-1(b)(1)(ii)(E)
(f) [ ] Employee Benefit Plan or endowment fund in accordance
to Section 240.13d-1(b)(ii)(F)
(g) [ ] A parent holding company or control person in
accordance with Section 240.13d-1(b)(1)(ii)(G)
(h) [ ] A savings associations as defined in Section 3(b) of the
Federal Deposit Insurance Act (12 U.S.C 1813)
(i) [ ] A church plan that is excluded from the definition of an
investment company under section 3(c)(14) of
the Investment Company Act of 1940 (15 U.S.C 80a-3)
(j) [ ] Group, in accordance with Section 240.13d-1(b)(1)(ii)(J)
Item 4. Ownership.
(a) Amount beneficially owned: 2,825,205----------,
(b) Percent of class: 9.9%----------------------,
(c) Number of shares as to which such person has:
(i) Sole power to vote or to direct the vote
0--,
(ii) Shared power to vote or to direct the vote
0------,
(iii) Sole power to dispose or to direct the disposition of
0-----,
(iv) Shared power to dispose or to direct the disposition of
2,825,205------
Item 5. Ownership of Five Percent or Less of a Class.
If this statement is being filed to report the fact that as of the date hereof
the reporting person has ceased to be the beneficial owner of more than five
percent of the class of securities, check the following [ ].
INAPPLICABLE
Item 6. Ownership of More Than Five Percent on Behalf of Another Person.
Securities reported under Shared Dispositve Power include securities
owned by clients of Ingalls & Snyder LLC ("Ingalls"), a registered
broker dealer and a registered investment advisor, in accounts managed under
investment advisory contracts. Such clients include Ingalls & Snyder Value
Partners, LP.
All shares reported assume the exercise of all warrants owned by Gipson.
Item 7. Identification and Classification of the Subsidiary which Acquired
the Security Being Reported on By the Parent Holding Company.
INAPPLICABLE
Item 8. Identification and Classification of Members of the Group.
INAPPLICABLE
Item 9. Notice of Dissolution of Group.
INAPPLICABLE
Item 10. Certification.
By signing below I certify that, to the best of my knowledge
and belief, the securities referred to above were acquired and are held in the
ordinary course of business and were not acquired and are not held for the
purpose of or with the effect of changing or influencing the control of the
issuer of the securities and were not acquired and are not held in connection
with or as a participant in any transaction having that purpose or effect.
Signature.
After reasonable inquiry and to the best of my knowledge and
belief, I certify that the information set forth in this
statement is true, complete and correct.
Date: 1/08/10
BY: Ingalls & Snyder, LLC
/s/ THOMAS O. BOUCHER, JR
- ----------------------------------
(Signature)*
THOMAS O. BOUCHER, JR
- ----------------------------------
Manager
(Name/Title)
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
-----END PRIVACY-ENHANCED MESSAGE-----